Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma

Gastroenterology

Volumn 143, Issue 3, 2012, Pages

  Maréchal, Raphaël ^a   Bachet, Jean Baptiste ^b,c,d   MacKey, John R ^e   Dalban, Cécile ^f   Demetter, Pieter ^a   Graham, Kathryn ^e   Couvelard, Anne ^g   Svrcek, Magali ^h   Bardier Dupas, Armelle ^b,d   Hammel, Pascal ^g   Sauvanet, Alain ^g   Louvet, Christophe ^b,h   Paye, François ^b,h   Rougier, Philippe ^c,i   Penna, Christophe ^c,j   André, Thierry ^b,d   Dumontet, Charles ^k,l   Cass, Carol E ^e   Jordheim, Lars Petter ^k   Matera, Eva Laure ^k   Closset, Jean ^a   Salmon, Isabelle ^a   Devière, Jacques ^a   Emile, Jean François ^c,j   Van Laethem, Jean Luc ^a   more..

^a ERASME HOSPITAL   (Belgium)

^b SORBONNE UNIVERSITÉ   (France)

^c LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e UNIVERSITY OF ALBERTA   (Canada)

^f Georges Francois Leclerc Center   (France)

^g BEAUJON HOSPITAL   (France)

^h HÔPITAL SAINT ANTOINE   (France)

ⁱ HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^j HÔPITAL AMBROISE PARÉ   (France)

^k CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^l HOSPICES CIVILS DE LYON   (France)

more..

Author keywords

Biomarker; Drug Metabolism; Nucleoside Transporters; Pancreatic Cancer

Indexed keywords

DEOXYCYTIDINE KINASE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FLUOROURACIL; GEMCITABINE; OXALIPLATIN; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE SUBUNIT 1; UNCLASSIFIED DRUG;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG METABOLISM; DRUG TRANSPORT; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PANCREATICODUODENECTOMY; POSTOPERATIVE CARE; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL TIME; TISSUE MICROARRAY;

EID: 84865474189     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2012.06.006     Document Type: Article

References (36)

1. D. Li, K. Xie, R. Wolff Pancreatic cancer Lancet 363 2004 1049 1057 (Pubitemid 38410779)
2. H.A. Burris III, M.J. Moore, J. Andersen Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 1997 2403 2413 (Pubitemid 27251144)
3. W.F. Regine, K.A. Winter, R.A. Abrams Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial JAMA 299 2008 1019 1026 (Pubitemid 351347058)
4. H. Oettle, S. Post, P. Neuhaus Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial JAMA 297 2007 267 277 (Pubitemid 46143304)
5. J.P. Neoptolemos, D.D. Stocken, C. Bassi European Study Group for Pancreatic Cancer Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial JAMA 304 2010 1073 1081
6. J.R. Mackey, S.A. Baldwin, J.D. Young Nucleoside transport and its significance for anticancer drug resistance Drug Resist Update 1 1998 310 324
7. J.R. Mackey, S.Y.M. Yao, K.M. Smith Gemcitabine transport in Xenophus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters J Natl Cancer Inst 91 1999 1876 1881
8. M.W. Ritzel, A.M. Ng, S.Y. Yao Recent molecular advances in studies of the concentrative nucleoside transporter (CNT): identification and characterization of novel human and mouse proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides Mol Membr Biol 18 2001 65 72 (Pubitemid 32521598)
9. J.R. Mackey, R.S. Mani, M. Selner Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines Cancer Res 58 1998 4349 4357 (Pubitemid 28450036)
10. J. Garcia-Manteiga, M. Molina-Arcas, F.J. Casado Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'- difluorodeoxycitidine-induced cytotoxicity Clin Cancer Res 9 2003 5000 5008 (Pubitemid 37323307)
11. P. Huang, W. Plunkett Induction of apoptosis by gemcitabine Semin Oncol 15 1995 2403 2413
12. V.W. Ruiz van Haperen, G. Veerman, J.B. Vermorken 2',2'- difluoro-deoxycitidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines Biochem Pharmacol 46 1993 762 766 (Pubitemid 23262974)
13. W. Plunkett, P. Huang, C.E. Searcy Gemcitabine: preclinical pharmacology and mechanisms of action Semin Oncol 23 1996 3 15 (Pubitemid 26362189)
14. R. Mori, T. Ishikawa, Y. Ichikawa Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells Oncol Rep 17 2007 1201 1205
15. Y. Nakano, S. Tanno, K. Koizumi Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells Br J Cancer 96 2007 457 463 (Pubitemid 46215217)
16. H. Achiwa, T. Oguri, S. Sato Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer Cancer Sci 95 2004 753 757 (Pubitemid 39335096)
17. C.M. Galmarini Correlation of hENT1 expression and function with gemcitabine cytotoxicity in mantle cell lymphoma lines and clinical samples Haematologica 91 2006 866B
18. J.R. Kroep, W.J. Loves, C.L. van der Wilt Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity Mol Cancer Ther 1 2002 371 376
19. V. Sebastiani, F. Ricci, B. Rubio-Viquiera Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival Clin Cancer Res 12 2006 2492 2497
20. M.Y. Cao, Y. Lee, N.P. Feng Adenovirus-mediated ribonucleotide reductase R1 gene therapy of human colon adenocarcinoma Clin Cancer Res 9 2003 4553 4561 (Pubitemid 37248415)
21. R. Rosell, K.D. Danenberg, V. Alberola Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients Clin Cancer Res 10 2004 1318 1325 (Pubitemid 38365223)
22. G. Bepler, I. Kusmartseva, S. Sharma RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer J Clin Oncol 24 2006 4731 4737 (Pubitemid 46646245)
23. A.M. Bergman, P.P. Eijk, V.W. Ruiz van Haperen In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant Cancer Res 65 2005 9510 9516 (Pubitemid 41508021)
24. S. Nakahira, S. Nakamori, M. Tsujie Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer Int J Cancer 120 2007 1355 1363
25. J.J. Farrell, H. Elsaleh, M. Garcia Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer Gastroenterology 136 2009 187 195
26. R. Marchal, J.R. Mackey, R. Lai Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma Cancer 116 2010 5200 5206
27. L.M. McShane, D.G. Altman, W. Sauerbrei Reporting recommendations for tumour MARKer prognostic studies (REMARK) Br J Cancer 93 2005 387 391 (Pubitemid 43080010)
28. J. Spratlin, R. Sangha, D. Glubrecht The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma Clin Cancer Res 10 2004 6956 6961 (Pubitemid 39383046)
29. F.E. Harrell, K.L. Lee, D.B. Mark Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors Stat Med 15 1996 361 387 (Pubitemid 26072233)
30. R. Marchal, J.R. Mackey, R. Lai Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma Clin Cancer Res 15 2009 2913 2919
31. H. Fujita, K. Ohuchida, K. Mizumoto Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy Neoplasia 12 2010 807 817
32. E. Giovannetti, M. Del Tacca, V. Mey Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine Cancer Res 66 2006 3928 3935
33. H. Fan, A. Huang, C. Villegas The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments Proc Natl Acad Sci USA 94 1997 13181 13186
34. R. Ashida, B. Nakata, M. Shigekawa Gemcitabine sensitivity-related mRNA expression in endoscopic ultrasound-guided fine-needle aspiration biopsy of unresectable pancreatic cancer J Exp Clin Cancer Res 28 2009 83
35. H. Akita, Z. Zheng, Y. Takeda Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma Oncogene 28 2009 2903 2909
36. T. Conroy, F. Desseigne, Ychou FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 2011 1817 1825